A Prospective Study of Correlation of Fructosamine with Continuous Glucose Monitor in Diabetic Patients

Abstract

Objective: To validate fructosamine for estimating the average glucose over a 2-week interval by comparing it with continuous glucose monitors. Research Design and Method: In this prospective study, 129 patients with a history of diabetes mellitus type 1 or type 2 wore a continuous glucose monitor for 14 days. At the end of the study, blood work, including fructosamine, was performed and compared with the average glucose obtained from the continuous glucose monitor to validate the accuracy of fructosamine in estimating the average glucose. Bivariate Pearson correlation and Chi-square analyses and multivariable regression analyses were used to examine the linear relationships of the potential covariates of average glucose levels. Results: The majority of participants was male (55.05%), caucasian (88.40%), and had type II diabetes (66.90%) with a mean age of 59.74 years (+15.44). The CGM devices used by these participants were made by Librepro (76.0%), Dexcom (16%), and Medtronic (8%). A binary logistic regression showed that those with a fructosamine value of 300mMol/L had 39% odds (95% CI 5.08 - 294.0) of having an average glucose value of < 200mg/dL, P < .001. Iterative Chi-square analyses showed that for patients having a fructosamine threshold of 300mMol/L or less, 98% had a CGM determined average glucose value of < 200mg/dL. Conclusion: When the serum fructosamine is less than 300µmol/L, the average glucose over the previous two weeks is less than 200mg/dL in 98% of patients